India’s fast-evolving nutraceutical sector stands at a decisive inflection point. An inter-ministerial committee constituted earlier this year by the Union Health Ministry has submitted comprehensive recommendations that could fundamentally reshape the regulatory architecture governing nutraceuticals and health supplements. If adopted, these proposals would recalibrate oversight responsibilities, sharpen accountability, and redefine the balance between innovation and consumer protection.
Recasting Regulatory Boundaries
The committee was mandated to examine persistent regulatory challenges across the nutraceutical value chain—ranging from vitamins and minerals to probiotics, botanicals, plant extracts, product claims, and pricing practices. Its recommendations seek to bring long-awaited clarity by delineating the respective roles of food and drug regulators.
Under the proposed approach:
Products classified as food under the Food Safety and Standards Act, 2006, particularly those containing macronutrients such as proteins, carbohydrates, and fats that provide significant caloric value, would continue under the oversight of the Food Safety and Standards Authority of India (FSSAI).
Formulations containing vitamins, minerals, and amino acids in drug-like doses, dosage forms, and permitted excipients, as defined under the Drugs and Cosmetics Act, would be shifted to the regulatory domain of the Central Drugs Standard Control Organisation (CDSCO).
Disease-related and Disease Risk Reduction (DRR) claims, including assertions to cure, mitigate, or prevent specific diseases or disorders, would be regulated by CDSCO, while FSSAI would retain authority over nutritional and health claims explicitly permitted under the Food Safety and Standards (Claims and Advertisements) Regulations, 2018.
A key structural recommendation is the introduction of Good Manufacturing Practices (GMP) standards for nutraceuticals and health supplements—an important step toward strengthening quality assurance and manufacturing discipline in the sector.
The Rationale Behind Tighter Oversight
India’s nutraceutical market has benefited from a comparatively relaxed regulatory environment, enabling ease of entry and encouraging entrepreneurship. However, this flexibility has also resulted in regulatory grey areas, which in turn have facilitated misleading claims, inconsistent quality standards, and aggressive marketing practices—particularly around disease risk reduction.
Given that nutraceuticals are largely over-the-counter and discretionary products, the government’s concern over consumer protection is well founded. Enhanced scrutiny, especially of therapeutic and disease-related claims, is seen as essential to safeguard public health and maintain market integrity.
Industry Concerns and Global Context
The prospect of expanded CDSCO oversight has triggered apprehension within the industry, which has long advocated for nutraceuticals to remain predominantly within the food regulatory framework. Industry stakeholders argue that:
India’s current regulations are broadly aligned with Codex Alimentarius, the globally recognised benchmark developed under the aegis of the World Health Organization (WHO).
Regulatory models in the US, UK, Australia, Japan, China, and the EU treat nutraceuticals closer to foods than pharmaceuticals.
A single-window regulatory mechanism under FSSAI would reduce duplication, enhance predictability, and ensure uniform enforcement, rather than creating parallel oversight by two authorities.
The industry has also emphasised that empowering FSSAI to act decisively on misleading claims identified by the Advertising Standards Council of India (ASCI) could provide an effective, proportionate solution without imposing drug-style regulation across the board.
A High-Potential Sector at Stake
Beyond the regulatory debate lies a compelling growth story. India’s nutraceutical ecosystem is robust and rapidly expanding, with over 300 startups already active across categories. Rising health awareness, preventive healthcare adoption, and a growing middle class position the sector for sustained expansion—provided the regulatory environment remains enabling as well as credible.
Toward a Balanced and Future-Ready Framework
As deliberations continue, the challenge before policymakers is to avoid false binaries. Excessive regulation risks stifling innovation and discouraging responsible players, while insufficient oversight could erode consumer trust and compromise safety.
The need of the hour is a calibrated, risk-based regulatory framework—one that subjects drug-like formulations and disease-related claims to stringent scrutiny, while allowing genuine food-based supplements to operate under a facilitative regime. Close coordination between regulators, industry bodies, and self-regulatory institutions can help achieve this equilibrium.
Handled judiciously, this regulatory transition can strengthen credibility, protect consumers, and position India’s nutraceutical industry for sustainable, globally competitive growth—transforming regulatory reform from a perceived constraint into a strategic enabler.
